Related Experiment Video
Updated: Jan 11, 2026
13:45
Merkel Cell Polyomavirus Infection and Detection
Published on: February 7, 2019
10.3K
Molecular Characterization of Polyomavirus-Positive and Negative Merkel Cell Carcinoma
Poorva Vaidya1, Sharon Wu2, Dave Bryant2
1Division of Hematology/Oncology, UC Irvine School of Medicine, Orange, CA 92868, USA.
Cancers
|November 13, 2025
Summary
Genomic analysis of Merkel Cell Carcinoma (MCC) reveals distinct alterations in virus-negative tumors, suggesting new therapeutic targets beyond viral status for immune checkpoint inhibitors (ICIs).
Area of Science:
- Oncology
- Genomics
- Immunology
Background:
- Immune checkpoint inhibitors (ICIs) are standard frontline therapy for advanced Merkel Cell Carcinoma (MCC).
- However, only half of patients achieve durable benefit, necessitating alternative treatment strategies.
- Understanding the genomic landscape associated with treatment response is crucial.
Purpose of the Study:
- To differentiate genomic alterations linked to ICI response in MCC.
- To investigate distinct genomic profiles between virus-positive (VP) and virus-negative (VN)-MCC.
- To identify novel therapeutic targets by analyzing WES and WTS data.
Main Methods:
- Whole exome sequencing (WES) and transcriptome sequencing (WTS) were performed on 95 MCC cases.
- Computational pipelines identified viral status and tumor mutational burden (TMB).
- RNA-seq data characterized the tumor immune microenvironment.
Main Results:
- 57% of MCC cases were VP-MCC and 40% were VN-MCC.
- Virus-negative MCC exhibited higher TMB and distinct mutations (e.g., TP53, RB1, PIK3CA).
- Upregulated MAPK pathway activity, NK cell infiltration, and CD276 were observed in VN-MCC.
Conclusions:
- Merkel Cell Carcinoma (MCC) development and treatment response are not solely dictated by viral status.
- Transcriptome and tumor microenvironment analyses reveal potential alternative therapeutic targets.
- Genomic insights can guide personalized treatment strategies for MCC patients.
